Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165966 | 0.80 | TTR (0.35) | EDNRBEDNRAPOLBMYCCA1 | |
| SCHEMBL29945031 | 0.80 | NCOR2 (0.42) | EDNRBEDNRAKMT2AMEN1POLB | |
| SCHEMBL2319486 | 0.80 | NCOR2 (0.42) | EDNRBEDNRAKMT2AMEN1POLB | |
| SCHEMBL5818114 | 0.76 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL6888962 | 0.76 | TSHR (0.45) | KMT2AMEN1ATMPOLBALDH1A1 | |
| SCHEMBL11783880 | 0.74 | HTR2B (0.51) | HTR7HTR2BKMT2AMEN1ATM | |
| SCHEMBL8697389 | 0.74 | AKR1B1 (0.41) | — | |
| SCHEMBL5917355 | 0.74 | CA1 (0.32) | LMNACA1CA2KDM4E | |
| SCHEMBL2587914 | 0.74 | PPIA (0.40) | KMT2AALDH1A1 | |
| SCHEMBL1683233 | 0.73 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 922 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068405-B1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2019-05-01 | — | — | EP | claimed |
| EP-3323414-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| US-9493469-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | claimed |
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | MELINTA SUBSIDIARY CORP. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-111556872-B | Synthesis of borate derivatives and uses thereof | 梅琳塔治疗公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-114085243-B | Pyrrolo [1,2-f ] [1,2,4] triazines useful for the treatment of respiratory syncytial virus infection | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4356736-A2 | SYNTHESIS OF BORONATE SALTS | Melinta Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3604316-B1 | SYNTHESIS OF BORONATE SALTS | MELINTA THERAPEUTICS INC (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023215335-A1 | FUNCTIONALIZED PSYCHOACTIVE COMPOUNDS | LUCY SCIENTIFIC DISCOVERY (CA) | 2023-11-09 | — | — | WO | disclosed |
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | disclosed |
| US-5464617-A | 1H-2,6a-diazacyclobut(cd)indene-6-carboxylic acid derivatives, antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1995-11-07 | — | — | US | disclosed |
| US-5463062-A | Inhibitors of glucose-6-phosphatase system | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-10-31 | — | — | US | disclosed |
| EP-0672660-A2 | Substituted cyclohexanol-esters, their use to treat illnesses and pharmaceutical preparations | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-20 | — | — | EP | disclosed |
| EP-0671392-A1 | Substituted propane derivatives, process for their preparation and use of the compounds for the treatment of illnesses | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-13 | — | — | EP | disclosed |
| EP-0620225-A1 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1994-10-19 | — | — | EP | disclosed |
| EP-0587088-A1 | Derivatives of substituted cyclohexane, their process of preparation and their application with the treatment of diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-16 | — | — | EP | disclosed |
| WO-1990000551-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0350950-A1 | Process for the preparation of quinoline antibacterial compounds | ABBOTT LABORATORIES (US) | 1990-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | ADH5, ADH1A, ADH7 | HTR7 4113/4885HTR2B 3508/4885EDNRB 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.